G
Günther G. Steger
Researcher at Medical University of Vienna
Publications - 243
Citations - 11875
Günther G. Steger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 41, co-authored 238 publications receiving 10859 citations. Previous affiliations of Günther G. Steger include University of Vienna.
Papers
More filters
Journal ArticleDOI
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
John F.R. Robertson,Günther G. Steger,Patrick Neven,Sandro Barni,F. Gieseking,Franco Nolè,Kathleen I. Pritchard,Frances P. O'Malley,Sergio Daniel Simon,Bella Kaufman,Lubos Petruzelka +10 more
TL;DR: Results indicate that fulvestrant may be a suitable treatment option in extensively pre-treated patients with HER2-positive, hormone receptor-positive ABC, and further exploration of its use in this patient population is warranted.
Journal Article
Karyotype and prognosis in non-Hodgkin lymphoma.
H Pirc-Danoewinata,Andreas Chott,E Onderka,Johannes Drach,E Schlögl,Ulrich Jäger,F Thalhammer,H Nowotny,D Aryee,Günther G. Steger +9 more
TL;DR: Clinical data and chromosomal aberrations in 70 adult patients with newly diagnosed NHL followed for a median of 20 months are correlated and cytogenetic analysis provides information about the complexity of genetic changes in NHL.
Journal ArticleDOI
Simultaneous occurrence of t(14;18) and t(8;22) common acute lymphoblastic leukemia.
C. Marosi,Peter Bettelheim,Andreas Chott,Ursula Köller,G. Kreiner,Günther G. Steger,Ulrich Jäger,H Pirc-Danoewinata,Klaus Lechner +8 more
TL;DR: A young male patient progressed rapidly from localized abdominal lymph node enlargement to overt acute lymphoblastic leukemia, and despite aggressive treatment, he died of progressive CNS leukemia 5 months after initial presentation.
Journal ArticleDOI
Fulvestrant and male breast cancer: a case series
Flora Zagouri,Theodoros N. Sergentanis,Dimosthenis Chrysikos,Eleni Zografos,Margaretha Rudas,Günther G. Steger,Georgios Zografos,Rupert Bartsch +7 more
TL;DR: women with HER2 positive MBC and trastuzumab related cardiotoxicity in the elderly: a role for cardiovascular risk factors.
Journal ArticleDOI
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
István Láng,Moshe Inbar,Zsuzsanna Kahán,Richard Greil,Semir Beslija,Salomon M. Stemmer,Bella Kaufman,Z. Zvirbule,Günther G. Steger,Diethelm Messinger,Thomas Brodowicz,Christoph C. Zielinski +11 more
TL;DR: Safety data from a randomised, phase III study evaluating first-line bevacizumab plus paclitaxel or capecitabine for locally recurrent or metastatic breast cancer is in-line with safety data reported in previous phase III trials.